Close menu




September 8th, 2025 | 07:10 CEST

Opendoor, Almonty Industries, BioNTech – Great opportunities outside the tech bubble

  • Mining
  • Tungsten
  • Defense
  • Technology
  • Gold
  • Biotechnology
  • RealEstate
Photo credits: pixabay.com

While the Nasdaq 100 continued to lose momentum last week, along with leading tech stocks, the crisis metal gold celebrated a new all-time high at USD 3,586 per ounce. The escalating geopolitical crises and the intensifying trade war between the US and China are likely to drive prices for critical raw materials in the long term. Western producers remain attractively valued.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: ALMONTY INDUSTRIES INC. | CA0203987072 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    BioNTech – Positive study data gives wings

    Despite the weakness of the overall market, the trading week ended with a 7-day gain of 12.89% to USD 112.89 for the German biotech hopeful. Following the stock's hype during the coronavirus pandemic and its subsequent decline after the vaccine, billions vanished from the order books. However, new hopes are emerging in the field of cancer research.

    The Mainz-based company announced a decisive study success with the active ingredient BNT323. In a significant, pivotal Phase 3 study in China, the drug, developed in collaboration with Chinese partner Duality Biologics, outperformed Roche's competing product in a particularly difficult-to-treat form of breast cancer.

    Patients lived significantly longer without disease progression, marking a clear success in achieving the study's "primary endpoint". For BioNTech, this represents its first major breakthrough in oncology. Chief Medical Officer Özlem Türeci described the result as a "milestone" in the Company's cancer research.

    BNT323 belongs to the class of antibody-drug conjugates (ADC). The principle: an antibody transports a chemotherapeutic substance directly to the tumor cell. This approach spares healthy cells and reduces side effects.

    BioNTech is now planning to expand clinical development globally. The drug is already being tested in another international Phase 3 trial in preparation for approval in Europe and the US. In addition, its potential in combination with other therapies is being explored.

    Almonty Industries – Attractive opportunity after the setback

    The setback suffered by Almonty shares after their successful Nasdaq listing could be a once-in-a-lifetime opportunity for long-term investors. When it comes to securing critical raw materials for the West, tungsten producer Almonty is not only at the top of the US government's list.

    Tungsten is considered one of the most important, yet underestimated, raw materials in global competition. It is essential for high-tech, industrial, and defense applications, with China holding a supply monopoly of over 80%. The Western world is looking for reliable sources of supply.

    Almonty Industries already operates a stable cash flow asset with the Panasqueira mine in Portugal. However, the real potential lies in the Sangdong mine in South Korea, one of the world's largest and highest-grade tungsten projects outside China, which is set to start production soon. Commissioning is planned for the second half of the year. Analysts estimate that Sangdong could cover over 80% of Western non-Chinese production at full capacity. Its economic viability is further supported by significantly higher ore grades compared to Panasqueira.

    Market conditions are playing into Almonty's hands. China's export restrictions and production losses in key mining areas such as Jiangxi and Hunan are exacerbating the global supply deficit. At the same time, prices for concentrates and processed products are rising. The US has classified tungsten as a critical raw material and plans to ban imports from China and Russia starting in 2027 - a move that is expected to provide Almonty with a significant geopolitical tailwind by then at the latest.

    The Company is in a solid financial position. Its Nasdaq listing raised USD 90 million, with a further USD 25 million in cash available at the end of the quarter. A purchase agreement with the US Department of Defense, along with minimum price guarantees for tungsten and molybdenum, provides strong planning security. Furthermore, entering downstream processing through its own oxide plant could also significantly increase margins.

    Analysts at GBC Research forecast revenues of EUR 212 million for 2027, with a net margin of around 40%. All analysts covering Almonty currently recommend the stock as a "Buy". With a current market capitalization of around CAD 1.34 billion, many market participants see further upside potential, especially following the recent price setback, which dropped from a high of CAD 8.66 to the current level of CAD 5.71.

    Opendoor – Meme stock on the rise

    The meme hype is picking up again, a sign, at least in the past, that the overall market could be at a turning point. One of these hyped stocks is Opendoor, a US iBuyer company that enables private individuals to sell residential properties quickly by generating instant cash offers online, purchasing properties "as is," organizing necessary repairs, and then reselling them.

    Last Thursday, Opendoor shares reached their highest level since August 2022, with a daily gain of over 16% and a price of USD 5.96. The rally is being driven by short squeeze fantasies and the support of prominent investors such as Eric Jackson of EMJ Capital, who sees Opendoor as a "leading cult stock." On social media, he called for the return of co-founder Keith Rabois to the board and announced that he himself would seek a seat on the board. Jackson also caused a stir with his attempt to win rapper Drake as a shareholder.

    From a fundamental standpoint, Opendoor reported Q2 revenue of USD 1.6 billion and achieved a positive adjusted EBITDA of USD 23 million, the first since 2022. However, the Company expects figures to decline again in Q3. Leadership changes have also drawn attention: CEO Carrie Wheeler recently stepped down, with Shrisha Radhakrishna now acting as interim CEO. Wheeler's sale of shares worth USD 35 million in the run-up to the rally also drew criticism.

    In addition to the focus on artificial intelligence, the return to Nasdaq compliance also helped give the stock new momentum. Nevertheless, 24% of freely tradable shares remain shorted, a factor that could continue to cause extreme price movements. Since the beginning of the year, the share price has risen by over 270%.


    BioNTech reported successful study results. The meme hype is driving Opendoor to a new three-year high. Almonty Industries is likely to benefit from US policy and offers an attractive entry point after the setback.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by André Will-Laudien on October 21st, 2025 | 07:45 CEST

    AI boom and DAX fireworks! Another 100% with NetraMark, Bayer, and Novo Nordisk

    • AI
    • Biotechnology
    • Biotech
    • Pharma

    Savvy investors are already taking notice! Artificial intelligence is revolutionizing drug research and radically reducing development costs. Algorithms are discovering molecular patterns that even the most experienced researchers would overlook, thus accelerating the path from laboratory to patient. Whether in oncology, rare diseases, or metabolic disorders, big data-driven models now enable more precise drug predictions and more realistic simulations of clinical outcomes. Those who understand AI can profit handsomely from the next biotech boom. You just have to muster the courage to finally get involved!

    Read

    Commented by Carsten Mainitz on October 21st, 2025 | 07:40 CEST

    Power Metallic Mines, RENK, BYD – An explosive combination! And the winners are?

    • Mining
    • Copper
    • Nickel
    • Gold
    • CriticalMetals
    • Electromobility
    • Defense

    Many topics are dominating the headlines. Peace in Gaza – and soon in Ukraine? This prospect initially put a significant damper on defense stocks – but only temporarily. After just a few days of correction, prices are already rising again. Gold at an all-time high is another major topic being covered in the media. Meanwhile, the geopolitical shifts we were reluctant to acknowledge for far too long are now catching up with many companies: China is cutting the world off from critical raw materials and rare earths. Read here to find out how investors can identify promising high-potential opportunities in this constellation.

    Read

    Commented by André Will-Laudien on October 21st, 2025 | 07:35 CEST

    Gold USD 4,300 and Silver USD 53 – Buying frenzy at Silver North, First Majestic, Nel ASA, and JinkoSolar

    • Mining
    • Silver
    • Gold
    • renewableenergies
    • Solar
    • Energy

    Silver has been shorted by many investment banks for several years because sufficient supply was available from Mexico and other producing countries. The tide has turned. Over the past 12 months, the precious metal has caught up with its big brother gold, gaining 54%. There are several reasons for the scarcity-driven rally: there are only around 250 active silver mines worldwide, compared to around 1,400 gold mines. In addition, silver has massively expanded its importance as an industrial metal: it is indispensable in high-tech, e-mobility, defense, and medical technology. As a result, less and less physical silver is available to investors, while inventories on the futures markets continue to decline. Now is the time to take a position in silver. Alongside industry giants such as First Majestic, Silver North is among the most promising beneficiaries of the new silver boom.

    Read